FOXO1 and neoplasm: A recent study by Chen et al. has indicated the anti-tumor capacities of FOXO1 in GBMs favor prolonged cell survival and decreased migration, invasion, cell adhesion (EMT), and drug resistance to chemotherapeutic agents such as TMZ, BCNU, or cisplatin [129].